Danny Feijtel

Mr. Danny Feijtel

Molecular Genetics, Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Cell
Verified
Journal Article
Closed access
MBMarjolein P. Baar
Marjolein P. Baar
RBRenata M.C. Brandt
Renata M.C. Brandt
DPDiana A. Putavet
Diana A. Putavet
JKJulian D.D. Klein
Julian D.D. Klein
KDKasper W.J. Derks
Kasper W.J. Derks
PKPeter L.J. de Keizer
Peter L.J. de Keizer

1 August 2018 in Cell Reports
Verified
Journal Article
Open access
MSMark Schmitt
Mark Schmitt
MSMatthias Schewe
Matthias Schewe
ASAndrea Sacchetti
Andrea Sacchetti
DFDanny Feijtel
Danny Feijtel
WGWesley S. van de Geer
Wesley S. van de Geer
Riccardo FoddeRiccardo Fodde
Riccardo Fodde
IBD syndromes such as Crohn's disease and ulcerative colitis result from the inflammation of specific intestinal segments. Although many studies have reported on the regenerative response of intestinal progenitor and stem cells to tissue injury, very little is known about the response of differentiated lineages to inflammatory cues. Here, we show that acute inflammation of the mouse small intestine is followed by a dramatic loss of Lgr5+ stem cells. Instead, Paneth cells re-enter the cell cycle, lose their secretory expression signature, and acquire stem-like properties, thus contributing to the tissue regenerative response to inflammation. Stem cell factor secretion upon inflammation triggers signaling through the c-Kit receptor and a cascade of downstream events culminating in GSK3β inhibition and Wnt activation in Paneth cells. Hence, the plasticity of the intestinal epithelium in response to inflammation goes well beyond stem and progenitor cells and extends to the fully differentiated and post-mitotic Paneth cells.

1 January 2021 in Theranostics
Verified
Journal Article
Open access
DFDanny Feijtel
Danny Feijtel
GDGabriela N. Doeswijk
Gabriela N. Doeswijk
NVNicole S. Verkaik
Nicole S. Verkaik
JHJoost C. Haeck
Joost C. Haeck
DCDaniela Chicco
Daniela Chicco
JNJulie Nonnekens
Julie Nonnekens
Patients with neuroendocrine tumors (NETs) can be treated with peptide receptor radionuclide therapy (PRRT). Here, the somatostatin analogue octreotate radiolabeled with lutetium-177 is targeted to NET cells by binding to the somatostatin receptor subtype 2 (SST2). During radioactive decay, DNA damage is induced, leading to NET cell death. Although the therapy proves to be effective, mortality rates remain high. To appropriately select more optimal treatment strategies, it is essential to first better understand the radiobiological responses of tumor cells to PRRT.

9 April 2021 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
GTGiulia Tamborino
Giulia Tamborino
JNJulie Nonnekens
Julie Nonnekens
MSMarijke De Saint-Hubert
Marijke De Saint-Hubert
LSLara Struelens
Lara Struelens
DFDanny Feijtel
Danny Feijtel
MKMark W. Konijnenberg
Mark W. Konijnenberg
Rationale: To build a refined dosimetry model for [177Lu]Lu-DOTA-[Tyr3]octreotate (177Lu-DOTATATE) in vivo experiments enabling the correlation of absorbed dose with double strand breaks (DSBs) induction and cell death. Methods: Somatostatin receptor type-2 (SSTR2) expression of NCI-H69 xenografted mice, injected with 177Lu-DOTATATE, was imaged at 0, 2, 5, 11 days. This was used as input to reconstruct realistic 3 dimensional heterogeneous activity distributions and tissue geometries of both cancer and heathy cells. The resulting volumetric absorbed dose rate distributions were calculated using GATE Monte Carlo code and compared to homogenous dose rate distributions. The absorbed dose (0-2 days) on µm-scale sections was correlated with DSBs induction, measured by γH2AX foci. Moreover, the absorbed dose on larger mm-scale sections delivered over the whole treatment (0-14 days) was correlated to the modelled in vivo survival to determine the radiosensitivity parameters α and β for comparison with experimental data (cell death assay, volume response) and external beam radiotherapy (EBRT). The DNA-damage repair half-life Tμ and proliferation doubling time TD were obtained by fitting the DSBs and tumor volume data over time. Results: A linear correlation with a slope of 0.0223 DSBs/cell mGy-1 between the absorbed dose and the number of DSBs/cell has been established. The heterogeneous dose distributions differ significantly from the homogenous dose distributions, with their corresponding average S-values diverging at 11 days up to +58%. No significant difference between modelled in vivo survival is observed in the first 5 days when using heterogeneous and uniform dose distributions, respectively. The radiosensitivity parameter analysis for the in vivo survival correlation indicates that the minimal effective dose rates for cell kill are 13.72 mGy/h and 7.40 mGy/h, with α=0.14 Gy-1 and 0.264 Gy-1, respectively and α/β=100 Gy; decreasing the α/β leads to a decrease in the minimal effective dose rate for cell kill. Within the linear quadratic (LQ) model, the best matching in vivo survival correlation (α=0.1 Gy-1, α/β=100 Gy, Tµ=60 h, TD=14.5 d) indicates a relative biological effectiveness value of 0.4 in comparison to EBRT. Conclusion: Our results demonstrate that accurate dosimetric modelling is crucial to establish dose-response correlations enabling optimization of treatment protocols.